NEWPORT NEWS, Va., Nov. 23, 2010 /PRNewswire/ -- Dilon Diagnostics announced today that its GammaLoc® gamma-guided biopsy system is being implemented around the world, as an accessory to the Dilon 6800® Gamma Cameras in North and Central America, Europe, the Middle East and Asia. The GammaLoc system accessory complements the Dilon 6800 Gamma Camera, which is optimized to perform Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI).
The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the GammaLoc lesion-localization system for molecular imaging biopsy guidance in December 2009. Cynthia Lorino, M.D., a breast radiologist at Montgomery Breast Center in Montgomery, Ala., and principal investigator for the FDA clinical trial of GammaLoc, says the future of breast imaging is molecular with supporting systems like GammaLoc. “BSGI allows us to find disease that ultrasound, MRI and mammogram may miss,” said Dr. Lorino. “The GammaLoc system is much easier on the patient than MRI biopsy.” Lorino has performed many GammaLoc procedures since implementing the system.
MRI biopsy requires the patient to remain in the prone position during time-consuming sequences obtained before and after targeting, often resulting in substantial patent discomfort. The GammaLoc allows for upright breast biopsies with optimal patient comfort. The entire system is small and portable, allowing physicians to perform molecular imaging guided biopsy procedures anywhere on site.
“Data consistently demonstrates that BSGI helps the physician pinpoint diagnosis for optimal treatment planning,” said Robert Moussa, President and CEO of Dilon Diagnostics. “GammaLoc further strengthens Dilon’s mission to provide innovative ways to continue the fight against breast cancer.”
About BSGI
As a follow-up to mammography, BSGI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as dark spots on the BSGI image.
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon’s cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.
SOURCE Integrated Marketing Solutions Inc.
